Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib

Nilotinib has significant efficacy in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) and in patients with CML-CP or CML in accelerated phase (CML-AP) after imatinib failure. We investigated the occurrence of cross-intolerance to nilotinib in imatinib-intolerant pati...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Cortes, Jorge E., Hochhaus, Andreas, le Coutre, Philipp D., Rosti, Gianantonio, Pinilla-Ibarz, Javier, Jabbour, Elias, Gillis, Kathryn, Woodman, Richard C., Blakesley, Rick E., Giles, Francis J., Kantarjian, Hagop M., Baccarani, Michele
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Hematology 2011
Schlagworte:
Clinical Trials and Observations
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4186645/
https://ncbi.nlm.nih.gov/pubmed/21467546
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-11-318949
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge